Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment

Multicentre , non-randomized, prospective clinical trial to assess efficacy of Nivolumab in treatment of nasopharyngeal cancer who progressed during or after platinum-based chemotherapy . Patients disqualified from radical therapy . The total number of patients was estimated for 32.

Trial Details

NCT ID
NCT04875611
Phase
PHASE2
Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Status
RECRUITING
Cancer Type
Nasopharyngeal Head and Neck Cancer
Interventions
  • Opdivo
Locations (sample)
  • Bialystok, Poland|53.13333,23.16433
  • Gdansk, Poland|54.35227,18.64912
  • Gliwice, Poland|50.29761,18.67658
  • Kielce, Poland|50.87033,20.62752

Key Eligibility Criteria

  • Age \> 18 years old
  • Histological or cytological documentation of squamous cell carcinoma.
  • Primary tumor location in nasopharynx
  • Previous, documented failure on platinum-based chemotherapy or progression of the disease during platinum-based chemotherapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Nasopharyngeal Head and Neck Cancer Trials on Trialify →